Sheikh Mohamed Mohamed
Toyo University
Dr. M. Sheikh Mohamed, is a post-doctoral researcher at Bio-Nano Electronics Research Centre, Toyo University, Japan with nearly 8 years of research experience in Bio-Nano Fusion Sciences, with a focus on synthesis and application of multifunctional nanoparticles for cancer theranostics. He has received best young researcher and best poster awards at International conferences and has published 15 peer-reviewed research articles with five cover pages in reputed journals, which have also been featured as news articles. Previously, he received the University Gold Medal during his M.Phil. in India and subsequently the prestigious Monbukagakusho Scholarship to pursue his Ph.D. in Japan.
Introduction:Brain tumors/cancer remains an unresolved challenge despite surgery, radio- and chemotherapy options, largely due to presence of physiological barriers, highly aggressive tumors, poor prognosis, and non-specific... [ view full abstract ]
Introduction:
Brain tumors/cancer remains an unresolved challenge despite surgery, radio- and chemotherapy options, largely due to presence of physiological barriers, highly aggressive tumors, poor prognosis, and non-specific drug accumulation. Nanomedicine provides a window of hope with the promise of overcoming these hurdles by delivering the requisite therapeutic components to desired regions of brain, surpassing the physiological barrier, without causing any unwarranted side-effects.
Methods:
Ribosome inactivating protein/quantum dots (QDs) loaded, hybrid solid-lipid nanoparticles (HSLNs) with dual, cancer and angiogenesis recognition ligands were developed for glioblastoma therapy and imaging. Intracranial glioma xenograft mice were used for intravenous administration of the nanoformulation and observations thereof.
Results:
The nanoformulation exhibited excellent stability in aqueous suspension with a shelf life of more than a year. Drug loading efficacy was a commendable 66 % with a sustained release pattern. Nil toxicity was observed on intravenous administration to mice with the biochemical, hematological, histopathological, weight and behavioral parameters advocating the biocompatibility of HSLNs. The formulation exhibited extended blood circulation period and reduced hepatobiliary uptake. Dual-targeted QD-HSLNs successfully trespassed the blood brain barrier (BBB) and accumulated specifically in intracranial tumors, and were retained therein for approximately 72h. The HSLNs were found to diffuse across the fibrotic tissue and penetrated the deeper core of tumor. While mice in non-targeted and single targeted therapeutic versions succumbed to growing tumors within a month, the dual targeted nanoformulation exhibited complete tumor regression in 60 % of mice, extending their survival to nearly 7 months.
Discussion:
Herein we present a pragmatic nanoformulation, based on highly biocompatible and FDA approved components for a precision-targeted anti-glioma therapy. So far, clinical use nanoformulations have shown to cure less that 50 % of subjects accompanied by severe side-effects. However, in our study, 60 % of test subjects were completely cured of tumors while the remaining 40 % presented a tumor regression of near to 90 %. We believe that extending the treatment, could further enhance the therapeutic outcome. These results are much superior to the present clinically approved formulations for treatment of various cancers. The resultant product is currently under discussion for technology transfer.
